Loading...
Bienvenue sur la collection HAL du laboratoire de BECCOH
Quelques conseils pour une publication "idéHALe"
• Pensez à respecter la signature institutionnelle
Université Paris-Saclay, UVSQ, BECCOH, 92104, Boulogne-Billancourt, France..
• Participez à l'accès ouvert
N'attendez pas : dès que votre article est en ligne, déposez dans Hal sa version acceptée pour publication et indiquez un embargo de 6 mois.
La loi pour une république numérique vous autorise en effet à partager cette version 6 mois après publications, quelque-soit l'éditeur
Plus d'informations Archives Ouverte : quid de mes droits d'auteurs ?
• Vous souhaitez disposer d'une page web référençant toutes vos publications ?
Créez vous en 5 minutes un idHal et un CVHAL
N'hésitez pas à nous contacter pour toutes questions,
nous serions ravis d'échanger avec vous hal.bib@uvsq.fr
nous serions ravis d'échanger avec vous hal.bib@uvsq.fr
Dernières Publications en accès ouvert dans Hal
-
-
Paul Takam Kamga, Marie Mayenga, Louise Sebane, Adrien Costantini, Catherine Julie, et al.. Colony stimulating factor-1 (CSF-1) signalling is predictive of response to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer, 2024, 188, pp.107447. ⟨10.1016/j.lungcan.2023.107447⟩. ⟨hal-04517531⟩
-
Alexander Stratigos, Claus Garbe, Clio Dessinioti, Celeste Lebbe, Alexander van Akkooi, et al.. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023. European Journal of Cancer, 2023, 193, pp.113252. ⟨10.1016/j.ejca.2023.113252⟩. ⟨inserm-04209605⟩
-
Alexander Stratigos, Claus Garbe, Clio Dessinioti, Celeste Lebbe, Alexander van Akkooi, et al.. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention–Update 2023. European Journal of Cancer, 2023, 193, pp.113251. ⟨10.1016/j.ejca.2023.113251⟩. ⟨inserm-04210036⟩
-
Julien Taïeb, Olivier Bouche, Thierry André, Karine Le Malicot, Pierre Laurent-Puig, et al.. Avelumab vs Standard Second-Line Chemotherapy in Patients with Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial. JAMA oncology, 2023, 9 (10), ⟨10.1001/jamaoncol.2023.2761⟩. ⟨hal-04322943⟩
-
-
-
-
-
Mots clés
Assisted reproductive techniques
Dabrafenib
Circulating cell-free DNA
Adapted physical activity molecular diagnosis oligometastatic disease pancreatic adenocarcinoma KRAS mutation
Anti-PD1 blockade
Advanced
BRAF V600-mutation
Colorectal cancer
Follow-up
Adjuvant
BRAFV600E
Resistance
Cancer
BRAFV600E mutation
Anti-CTLA-4
Radiofrequency ablation
Colon cancer
Abdominal pain
Invasive cutaneous squamous cell carcinoma
Safety
Diagnosis
Surgical excision
TNM classification
Adverse events
Biomarker
Trametinib
Immunotherapy
Metastatic cSCC
2-chlorodeoxyadenosine
Chemoresistance
Polyomavirus
Antibody-drug conjugate
Radiotherapy
Abscopal effect colorectal cancer intratumoral immunotherapy liver metastases radiofrequency
Lung adenocarcinoma
Colorectal carcinoma
Abscopal effect anti-PD-1 antibody melanoma nivolumab pembrolizumab radiotherapy
BRAFV600-mutant melanoma
Anti-Tumor pharmacology
Immunomodulation
Biomarkers Colonic neoplasms Machine learning Prognosis Tumour infiltrating lymphocytes
Non-small cell lung cancer
Merkel cell carcinoma
ACTH
BRAF V600E
Crizotinib
Body mass index
Circulating tumor DNA
ALK rearrangement
Staging
Prevention
Anti-PD-1
Cutaneous squamous cell carcinoma
Advanced melanoma
Anti-PD-1 antibody
Bisphosphonates bone lesion case report histiocytosis Langerhans cell histiocytosis review
Adjuvant therapy
Melanoma
Immune checkpoint inhibitor
Wnt
Mesenchymal stromal cells
Androgen insensitivity
Molecular targeted therapies
Sonic Hedgehog
Prognostic
Locally advanced
BRAF
Langerhans cell histiocytosis
ADN tumoral circulant
Immunohistochemistry
Abscopal effect
EGFR
Cancer bronchique non à petites cellules
AZD9291
Histiocytosis
Treatment
ALK
Acute generalized exanthematous pustulosis
Anti-CTLA-4 anti-PD-1 elderly immune checkpoint inhibitors melanoma nonagenarian octogenarian
Children
Biomarkers
Nivolumab
Anti-PD1
Plasma
Systemic therapy
Cemiplimab
Prognosis
Beta-catenin
Targeted therapy
Survival
Antineoplastic agents
Gastric bypass
Osimertinib
Biliopancreatic diversion
Metastatic
AML
Bariatric surgery
Chemotherapy
Allelic imbalance
Adjuvant FOLFOX